Concurrent treatment of chronic psoriasis and asthma with ustekinumab

Ajay Amarnani, Ken S. Rosenthal, Jorge M. Mercado, Robert T. Brodell

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


A 56-year-old woman with a 40-year history of guttate flares of psoriasis associated with stress and infection as well as chronic asthma was treated with subcutaneous injections of ustekinumab, repeated after 1 month and then every 3 months. Her psoriasis completely resolved, and her capacity for exercise was markedly increased and asthma maintenance medications were no longer needed. Ustekinumab is a human monoclonal antibody that binds the p40 subunit of IL-12 and IL-23 to limit the progression of the Th1 and Th17 inflammatory immune responses that maintain many autoimmune and inflammatory diseases. Th17-related responses drive inflammation during late stages of chronic asthma and can also be blocked by ustekinumab. Blocking the underlying cytokine-mediated inflammatory responses for psoriasis with ustekinumab can also treat other chronic inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)63-66
Number of pages4
JournalJournal of Dermatological Treatment
Issue number1
StatePublished - Feb 1 2014
Externally publishedYes


  • Asthma
  • Chronic inflammation
  • IL-12p40
  • Psoriasis
  • Ustekinumab

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Concurrent treatment of chronic psoriasis and asthma with ustekinumab'. Together they form a unique fingerprint.

Cite this